Our application window is now closed!
We will be announcing the teams selected to move through to the next stage in Spring 2026.
Longitude Prize on ALS
The £7.5 million (~$10 million) Longitude Prize on ALS incentivises the use of AI-based approaches to transform drug discovery for amyotrophic lateral sclerosis (ALS), the most common form of motor neurone disease (MND).
Overview of the Prize
Interested in learning more about the Prize? Watch this to get an overview of how it works.
Timeline of the Prize
The Longitude Prize on ALS will run for five years and will comprise three key stages: Discovery, Prioritise and Validate
Interested in the Prize?
If you want to keep up with our progress, join our mailing list